Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03692403 · ClinicalTrials.gov registry record · Phase 2
Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT03692403 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT03692403, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
Interventions
- DRUG Placebo
- DRUG Quinagolide 360 µg
- DRUG Quinagolide 720 µg
- DRUG Quinagolide 1080 µg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-12-26 |
| Est. Completion | 2022-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03692403
The ClinicalTrials.gov registry entry for NCT03692403 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03692403 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03692403 about?
NCT03692403 is a clinical study titled "Randomized Trial Assessing Quinagolide Vaginal Ring for Endometriosis-related Pain". To evaluate the efficacy of three doses of quinagolide administered as an extended-release vaginal ring compared to placebo on reduction of moderate to severe endometriosis-related pain
What is the current status of trial NCT03692403?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2018-12-26. Estimated completion is 2022-02-14.
What interventions are being tested in trial NCT03692403?
The interventions under investigation include: Placebo (DRUG), Quinagolide 360 µg (DRUG), Quinagolide 720 µg (DRUG), Quinagolide 1080 µg (DRUG).
Who is sponsoring clinical trial NCT03692403?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.